A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Exclusion Criteria10

• Use of systematic anti-tumor therapy within 2weeks prior to the first dose；
• Presence of other malignancies in the past 5 years;
• Received major surgical surgery within 60 days before the first dose;
• Have received any surgery or invasive treatment within 4 weeks before the first use of the drug;
• Received palliative radiotherapy within 1 week before the first dose; received radical radiotherapy within 4 weeks before the first dose;
• Any known allergy to surufatinib or its components, camrelizumab, nab-paclitaxel, or gemcitabine;
• Received inducers or inhibitors of cytochrome P450 (CYP) 3A within 2 weeks or 5 half-lives (whichever is longer) before the first dose;
• Use of immunosuppressive drugs within 4 weeks before first dose;
• Known history of clinically significant liver disease, including active viral hepatitis infection or other active hepatitis or clinically significant moderate to severe cirrhosis;
• Patients who currently have hypertension that cannot be controlled by medication;